Investment Summary

Parkwalk invested in Itaconix (Revolymer as was) in April 2011 and July 2012 when the company successfully raised £25m on listing on AIM. We exited our holding in July 2018 at a loss for investors.

Revolymer, spun-out from Bristol University, has 2 core technologies based on amphiphilic polymers & encapsulation which have evolved into 4 platforms leading to multiple uses.

Itaconix is a specialty chemicals business focussed on controlled release, responsive encapsulation systems and delivery systems that improve the functional performance of its customers’ products for home care, personal care, coatings, adhesives and sealants.